Mechanism of action of vesicular monoamine transporter 2 (VMAT2) inhibitors in tardive dyskinesia: reducing dopamine leads to less "go" and more "stop" from the motor striatum for robust therapeutic effects.
CNS Spectr
; 23(1): 1-6, 2018 02.
Article
em En
| MEDLINE
| ID: mdl-29249207
ABSTRACT
Tardive dyskinesia can now be successfully treated by inhibiting the vesicular monoamine transporter type 2 (VMAT2).
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Tetrabenazina
/
Dopamina
/
Corpo Estriado
/
Proteínas Vesiculares de Transporte de Monoamina
/
Discinesia Tardia
Limite:
Animals
/
Humans
Idioma:
En
Revista:
CNS Spectr
Assunto da revista:
NEUROLOGIA
Ano de publicação:
2018
Tipo de documento:
Article